New cancer biotech emerges from Stanford research, with help of Nobel laureate Carolyn Bertozzi

A new solid tumor biotech based on research out of Stanford University is targeting the red-hot fields of cancer immunotherapy and antibody-drug conjugates.

TwoStep Therapeutics unveiled itself on Tuesday morning, and its bold bets — changing the immunotherapy field and bringing a new flavor to pharma’s en vogue oncology modality…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks